Mounjaro and other GLP-1 drugs may lower cancer risk in obese patients, according to a new study. Read more here.

Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials.

Eli Lilly is one of the top growing stocks at the moment. Learn the reasons why this might be a stock to consider.

People with obesity who took Eli Lilly's daily oral GLP-1 drug orforglipron lost an average of 12.4% of their body weight, ...

In a Phase 3 trial, drugmaker Eli Lilly and Company said it's oral GLP-1 pill showed similar results to injectable weight ...

Eli Lilly raised the price of its GLP-1, Zepbound, from about $125 to $165 and plans an additional hike next month that would ...

In the first Phase 3 trial of its once-daily oral GLP-1 pill in people with obesity, drugmaker Eli Lilly said Thursday that ...

Drugmaker Eli Lilly says after successful results in a phase 3 clinical trial, it expects to submit a GLP-1 weight loss pill ...

As Eli Lilly and Novo Nordisk have been battling it out to gain market share of the growing GLP-1 weight loss market, one ...

That drug is orforglipron, Eli Lilly’s GLP-1 drug that patients administer orally rather than through an injectable pen. The results of orforglipron’s Phase 3 Food and Drug Administration (FDA ...

Through innovation, cost discipline, legal action, and competitive pricing, Novo Nordisk has reasserted its leadership in the GLP-1 market. With a robust pipeline and global expansion, NVO is poised ...

The world’s largest pharmaceutical stock, Eli Lilly and Company LLY, is back in the green in 2025 as of the Apr. 21 close. Shares were down moderately in 2025 through mid-April. However, huge ...